Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Operating Grant: SARS-CoV-2 variants supplement stream 2

Université Laval

$100,000.00

COVID-19 Variant Network - Innovative therapeutic approaches for the 2019-novel coronavirus

EF 2020-21

Résumé
The 2019-novel coronavirus (SARS CoV-2) is a major sanitary and economical threat to all countries. Development of effective antivirals is a major global priority especially early in the epidemic when vaccines are unavailable. This proposal aims at discovering and evaluating active compounds by rational design through 3D modeling of key viral proteins and also by analyzing cellular gene signatures induced by the virus. In-depth evaluation of selected compounds will include in vitro, ex vivo (human bronchial epithelium tissues) and in vivo (animal models) studies. These approaches, mostly based on drug repurposing (new indication for an existing drug), will result in rapid identification of anti-SARS CoV-2 compounds with accelerated clinical development.
Programme
Operating Grant: SARS-CoV-2 variants supplement stream 2
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
442866
Name
Boivin Guy
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Special Cases
Projecttitle
COVID-19 Variant Network - Innovative therapeutic approaches for the 2019-novel coronavirus
Programtype2
Operating Grants
Orgnameinp2
Université Laval
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
Operating Grant: SARS-CoV-2 variants supplement stream 2
Keyworddelim
Antivirals; Combination; Coronavirus; Ferret; Hamster; Modeling; Polymerase; Repurposing; Synergy; Transcriptomic
Abstract
The 2019-novel coronavirus (SARS CoV-2) is a major sanitary and economical threat to all countries. Development of effective antivirals is a major global priority especially early in the epidemic when vaccines are unavailable. This proposal aims at discovering and evaluating active compounds by rational design through 3D modeling of key viral proteins and also by analyzing cellular gene signatures induced by the virus. In-depth evaluation of selected compounds will include in vitro, ex vivo (human bronchial epithelium tissues) and in vivo (animal models) studies. These approaches, mostly based on drug repurposing (new indication for an existing drug), will result in rapid identification of anti-SARS CoV-2 compounds with accelerated clinical development.
Competitiondate
202102
Approvedterm2
1 yr 0 mth
Pinamesdelim
Boivin, Guy; Finzi, Andrés; Liang, Chen; Lin, Sheng-Xiang
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $100,000~ $0~